Abbott Laboratories won Food and Drug Administration permission to enroll patients in a head-to-head clinical comparison of its ZoMaxx II drug-eluting coronary stent with Taxus Express 2 by Boston Scientific Corp. Abbott said the trial will involve 1,670 coronary artery disease patients at 80 centers. The company said it hoped to win FDA approval of ZoMaxx II by the end of 2007. -- by Mark Taylor
Abbott gets OK for clinical comparison of stents
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.